Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Rat (Rattus) MAP3K2 Anticorps:
anti-Human MAP3K2 Anticorps:
anti-Mouse (Murine) MAP3K2 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal MAP3K2 Primary Antibody pour ICC, ELISA - ABIN969272
Kurada, Li, Mulherkar, Subramanian, Prasad, Prabhakar: MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. dans The Journal of biological chemistry 2009
Show all 2 Pubmed References
Compound 1s displayed activity in cell-based assays in which it inhibited ERK5 (Montrer MAPK7 Anticorps) pathway activation in cells and inhibited cell migration in a scratch assay. Thus, we have identified a scaffold that has promising potential to be developed into a highly selective and potent inhibitor of MEKK2. Information from these SAR (Montrer SARDH Anticorps) studies provides specific guidance for the future design of MEKK2 inhibitor probes.
miR (Montrer MLXIP Anticorps)-34c-3p may regulate triple-negative breast cancer progression by directly targeting the 3'-untranslated region of mitogen-activated protein kinase kinase kinase 2 (MAP3K2).
Study found miR (Montrer MLXIP Anticorps)-186 expression significantly decreased in lung cancer tissues and cells and MAP3K2 expression increased in the same cancer tissues. Also, results confirmed that MAP3K2 is a target gene of miR (Montrer MLXIP Anticorps)-186 and both expression correlated with prognosis.
SMYD3-mediated methylation of MAP3K2 increases mutant K-Ras-induced activation of ERK1/2. (Review)
Restoration of miR17/20a in solid tumor cells enhances the natural killer cell antitumor activity by targeting Mekk2
HBXIP (Montrer HBXIP Anticorps) activated ERK1/2 through up-regulating MEKK2.
MEKK2 has a novel function as a regulator of ubiquitylation-dependent paxillin (Montrer PXN Anticorps) redistribution in breast tumour cells.
EBV microRNA BART (Montrer BSND Anticorps) 18-5p targets MAP3K2 to facilitate persistence in vivo by inhibiting viral replication in B cells.
Inhibitors of apoptosis proteins regulate myogenic differentiation by directly suppressing MEKK2/3-MEK5 (Montrer MAP2K5 Anticorps)-ERK5 (Montrer MAPK7 Anticorps) signaling.
methylation of MAP3K2 by SMYD3 increases MAP kinase signalling and promotes the formation of Ras-driven carcinomas
Erk5 (Montrer MAPK7 Anticorps) MAP kinase (Montrer MAPK1 Anticorps) is activated in response to PDGF (Montrer PDGFA Anticorps)-BB in the smooth muscle cell line MOVAS in a manner dependent on Mekk2, Mek1 (Montrer MAP2K1 Anticorps)/2, Mek5 (Montrer MAP2K5 Anticorps), PI3-kinase (Montrer PIK3CA Anticorps) and protein kinase C (PKC (Montrer PKC Anticorps)).
FGF2 (Montrer FGF2 Anticorps)/MEKK2 pathway mediates an alternative nonclassical pathway for beta-catenin (Montrer CTNNB1 Anticorps) activation, and this pathway is a key regulator of bone formation by osteoblasts
Stk38 (Montrer STK38 Anticorps) protein kinase (Montrer CDK7 Anticorps) has a role in inhibiting TLR9 (Montrer TLR9 Anticorps)-activated inflammatory responses by promoting MEKK2 ubiquitination in macrophages
MEKK2 is regulated through a phosphorylation-dependent association with 14-3-3 (Montrer YWHAQ Anticorps), a group of adapters that modulate dimerization and association between proteins
MEKK2 signaling contributes to right ventricular hypertrophy and altered myocardial inflammatory gene expression in response to hypoxia-induced pulmonary hypertension.
MEKK2 alone can suppress T-cell TGF-beta (Montrer TGFB1 Anticorps) responses. MEKK2 or MEKK3 (Montrer MAP3K3 Anticorps) can cause ERK1/2 to phosphorylate SMAD2 (Montrer SMAD2 Anticorps)/3 and suppress R-SMAD (Montrer SMAD1 Anticorps)-dependent transcription. MEKK2 and MEKK3 (Montrer MAP3K3 Anticorps) play overlapping roles in regulating Th-cell differentiation via TGF-beta (Montrer TGFB1 Anticorps)
Data show that HDAC4 (Montrer HDAC5 Anticorps) binds and promotes the deacetylation and activation of a key MAP3 kinase, MEKK2.
Data from experiments with Mekk2(-/-) mice show that MEKK2 may be required for controlling the strength of T cell receptor/CD3 (Montrer CD3E Anticorps) signaling.
PB1 (Montrer GPR97 Anticorps) domain mediates the association of MEKK2 and MEKK3 (Montrer MAP3K3 Anticorps) with MEK5 (Montrer MAP2K5 Anticorps) and that the respective PB1 (Montrer GPR97 Anticorps) domains of these kinases are critical for regulation of the ERK5 (Montrer MAPK7 Anticorps) pathway.
The protein encoded by this gene is a member of serine/threonine protein kinase family. This kinase preferentially activates other kinases involved in the MAP kinase signaling pathway. This kinase has been shown to directly phosphorylate and activate Ikappa B kinases, and thus plays a role in NF-kappa B signaling pathway. This kinase has also been found to bind and activate protein kinase C-related kinase 2, which suggests its involvement in a regulated signaling process.
mitogen-activated protein kinase kinase kinase 2
, MAP/ERK kinase kinase 2
, MAPK/ERK kinase kinase 2
, MEK kinase 2
, MEKK 2
, mitogen activated protein kinase kinase kinase 2
, protein kinase MEKK2b